1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

Journal of Medicinal Chemistry

Volumn 46, Issue 13, 2003, Pages 2774-2789

  Villhauer, Edwin B ^a,b   Brinkman, John A ^a,b   Naderi, Goli B ^a,b   Burkey, Bryan F ^a,b   Dunning, Beth E ^a,b   Prasad, Kapa ^a,c   Mangold, Bonnie L ^a,d   Russell, Mary E ^a,b   Hughes, Thomas E ^a,b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Metabolic and Cardiovascular Diseases Research   (United States)

^c Chemical Development   (China)

^d Drug Metabolism and Pharmacokinetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[(3 HYDROXY 1 ADAMANTYL)AMINO]ACETYL] 2 CYANOPYRROLIDINE; 1 [[2 (5 CYANOPYRIDIN 2 YL)AMINO]ETHYLAMINO]ACETYL 2 CYANOPYRROLIDINE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RAT STRAIN; STRUCTURE ACTIVITY RELATION;

ADAMANTANE; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD26; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MACACA FASCICULARIS; MALE; PYRROLIDINES; RATS; RATS, ZUCKER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037777695     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030091l     Document Type: Article

References (94)

1. (a) Yaron, A.; Nadier, F. Proline-Dependent Structural and Biological Properties of Peptides and Proteins. Crit. Rev. Biochem. Mol. Biol. 1993, 28, 31-81.
2. (b) Demuth, H.; Heins J. Catalytic mechanism of Dipeptidyl Peptidase-IV. In Dipeptidyl Peptidase-IV (CD26) in Metabolism and the Immune Response; Fleischer, B., Ed.; Landes, R. G.: Austin, TX, 1995; Vol. 3, pp 1-35.
3. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9-24.
4. (a) Jacotot, E.; Callebaut, C.; Blanco, J.; Krust, B.; Neubert, K.; Barth, A.; Hovanessian, A. G. Dipeptidyl-peptidase IV-B, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity. Eur. J. Biochem. 1996, 239, 248-258.
5. (b) Schneider, B. L.; Thevananther, S.; Moyer, M. S.; Walters, H. C.; Rinaldo, P.; Devarajan, P.; Sun, A. Q.; Dawson, P. A.; Ananthanarayanan, M. Cloning and Characterization of a Novel Peptidase from Rat and Human Ileum. J. Biol. Chem. 1997, 272, 31006-31015.
6. (c) Duke-Cohan, J. S.; Gu, J.; McLaughlin, D. F.; Xu, Y.; Freeman, G. J.; Schlossman, S. F. Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activate human T lymphocytes and modulate immune cell interactions. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 11336- 11341.
7. (d) Niedermeyer, J.; Enenkel, B.; Park, J. E.; Lenter, M.; Rettig, W. J.; Damm, K.; Schnapp, A. Mouse fibroblast-activation protein-conserved Fap gene oranization and biochemical function as a serine protease. Eur. J. Biochem. 1998, 254, 650-654.
8. (e) Chiravuri, M.; Schmitz, T.; Yardley, K.; Underwood, R.; Dayal, Y.; Huber, B. T. A Novel Apoptotic Pathway in Quiescent Lymphocytes Identified by Inhibition of a Post-Proline Cleaving Aminodipeptidase: A Candidate Target Protease, Quiescent Cell Proline Dipeptidase. J. Immunol. 1999, 163, 3092-3099.
9. (a) Holst, J. J. Glucagon-like peptide-1 (GLP-1) a newly discovered GI hormone. Gastroenterology 1994, 107, 1048-1055.
10. (b) Orsakov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 1992, 35, 701-711.
11. (c) Drucker, D. J. Glucagon-Like Peptides. Diabetes 1998, 47, 159-169.
12. (a) Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidylpeptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36), peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214, 829-835.
13. (b) Deacon, C. F.; Johnsen, A. H.; Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 1995, 80, 952-957.
14. (c) Kieffer, T. J.; McIntosh, C. H. S.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136, 3585-3596.
15. (d) Lene, H.; Deacon, C. F.; Orskov, C.; Holst, J. J. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140, 5356-5363.
16. Ahrén, B.; Holst, J. J.; Martensson, H.; Balkan, B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV Eur. J. Pharmacol. 2000, 404 (1/2), 239-245.
17. Deacon, C. F.; Hughes, T. E.; Holst, J. J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998, 47, (5), 764-769.
18. (a) Pederson, R. P.; White, H. A.; Schlenzig, D.; Pauly, R. P.; McIntosh, C. R. P.; Demuth, H. U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998, 47, 1258.
19. (b) Pauly, R. P.; Demuth, H.-U.; Rosche, R.; Schmidt, J.; White H. A.; Lynn F.; McIntosh, C. H. S.; Pederson, R. A. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide Metabolism 1999, 3, 385-389.
20. (c) Pospisilik, J. A.; Stafford, S. G.; Demuth, H.-U.; Brownsey, R.; Parkhouse, W.; Finegood, D. T.; McIntosh, C. H. S. Pederson, R. A. Long-Term Treatment with the Didpeptidyl Peptidase IV Inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker Rats. Diabetes 2002, 51, 943-950.
21. (a) Balkan, B.; Kwasnik, L.; Miserendino, R.; Holst, J. J.; Li, X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42 (11), 1324-1331.
22. (b) Mitani, H.; Takimoto, M.; Hughes T. E.; Kimur, M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fisher 344 rat substrain deficient in its enzyme activity. Japanese Journal of Pharmacology 2002, 88, 442-450.
23. (c) Mitani, H.; Takimoto, M and Kimura, M. Dipeptidyl peptidase IV inhibitor, NVP-DPP728, ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fisher 344 rats lacking its enzyme activity. Jpn J. Pharmacol. 2002, 88, 451-458.
24. Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, E. M.; Haigh, R.; Junien, J.-L.; Aubert, M. L. Chronic Inhibition of Circulating Dipeptidyl Peptidase-IV by FE 999011 Delays the Occurrence of Diabets in Male Zucker Diabetic Fatty Rats. Diabetes 2002, 51, 1461-1469.
25. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.-M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Wantanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6864-6879.
26. Holst, J. J.; Deacon, C. F. Inhibition of the activity of Dipeptidyl-Peptidase IV as a treatment for Type 2 Diabetes. Diabetes 1998, 47, 1663-1670.
27. (b) Zander, M.; Madsbad, S.; Madsen, J. L.; Holst, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes; a parallel-group study. Lancet 2002, 359, 824-830.
28. (a) Ahren, B.; Larsson, J.; Holst, J. J. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1997, 82, 473-478.
29. (b) Rachman, J.; Borrow, B. A.; Levy, J. C.; Turner R. C. Near normalizatoin of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40, 205-211.
30. (c) Nauck, M. A.; Wollschlager, D.; Werner, J.; Holst, J. J.; Orskov, C.; Creutzfeldt, W.; Willms, B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39, 1546-1553.
31. (d) Drucker, D. J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122 (2), 531-544.
32. (e) Egan, J.; Clocquet, A. R.; Elahi, D. The Insulinotropic Effect of Acute Exendin-4-administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2002, 87 (3), 1282-1290.
33. (a) Wettergren, A.; Schjoldager, B.; Martensen, P. E.; Myhre, J.; Christiansen, J.; Holst, J. J. Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 1993, 38, 665-673.
34. (b) Nauck, M. A.; Niedereichholz, U.; Ettler, R.; Holst, J. J.; Orskov, C.; Ritzel, R.; Schmigel, W. H. Glucagon-like peptide-1 inhibition of gastricemptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 1997, 273, E981-E988.
35. (c) Nauck, M. A. Is GLP-1 an incretin hormone? Diabetologia 1999, 42, 373-379.
36. (d) Egan, J.; Clocquet, A. R.; Elahi, D. The Insulinotropic Effect of Acute Exendin-4-Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2002, 87 (3), 1282-1290.
37. (a) Habener, J. F. Glucagonlike peptide-1 agonist stimulation of β-cell growth and differentiation. Curr. Opin. Endocrinol. Diabetes 2001, 8 (2), 74-81.
38. (b) Ling, Z.; Wu, D.; Zambre, Y.; Flamez, D.; Drucker, D. J.; Pipeleers, D. G.; Schuit, F. C. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 2001, 438 (4), 382-387.
39. (c) Aspelun, F.; Egan, J. M.; Slezak, L. A.; Sritharan, K. C.; Elahi, D.; Andersen, D. K. Glucagon-like peptide-1 and exendin-4 improve glucose tolerance and induce islet cell growth in pancreatitis in rats. Surg. Forum 2000, 51, 40-42.
40. (d) Kemp, D. M.; Habener, J. F. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology 2001, 142 (3), 1179-1187.
41. (e) Parkes, D. G.; Pittner, R.; Jodka, C.; Smith, P.; Young, A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metab. Clin. Exp. 2001, 50 (5), 583-589.
42. (f) Farilla, L.; Hui, H.; Berolotto, C.; Kang, E.; Bulotta, A.; Di Mario, U.; Perfetti, R. Glucagon-like Peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143 (11), 4397-4408.
43. (g) Abraham, E. J.; Leech, C. A.; Lin, J. C.; Zuelwski, H.; Habener, J. F. Insulinotropic Hormone Glucagon-Like Peptide-1 differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin- Producing Cells. Endocrinology 2002, 143 (8), 3152-3161.
44. (h) Tourrel, C.; Bailbe, D.; Lacorne, M.; Meile, M. J.; Kergoat, M.; Portha, B. Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the B-Cell Mass During the Prediabetic Period with Glucagon-Like Peptide-1 or Exendin-4. Diabetes 2002, 51, 1443-1452.
45. (i) Perfetti, R.; Zhou, J.; Doyle, M. E.; Egan, J. M. Glucagon-Like Peptide -1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expressoin and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats. Endocrinology 2000, 141 (12), 4600-4605.
46. (j) Li, Y.; Hansotia, T.; Yusta, B.; Ris, F.; Halban, P. A.; Drucker, D. J. Glucagon-like Peptide-1 Receptor Signaling Modulates beta Cell Apoptosis. J. Biol. Chem. 2003, 278 (1), 471-478.
47. (a) Flint, A.; Raben, A.; Ersboll, A. K.; Holst, J. J.; Astrup, A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. 2001, 25, 781-792.
48. (a) Doyle, M. E.; Egan, J. M. Glucagon-like peptide-1. Recent Prog. Horm. Res. 2001, 56, 377-399.
49. (b) Villanueva-Peñacarrillo, M. L.; Puente, J.; Redondo, A.; Clemente, F.; Valverde, I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in Type 1 and Type 2 rat diabetic models. Endocrine 2001, 15 (2), 241-248.
50. (c) Sandhu, H.; Wiesenthal, S. R.; MacDonald, P. E.; McCall, R. H.; Tchipashvili, V.; Rashid, S.; Satkunarajah, M.; Irwin, D. M.; Shi, Z. Q.; Brubaker, P. L.; Wheeler, M. B.; Vranic, M.; Efendic, S.; and Giacca, A. Glucagon-Like Peptide 1 increases inslin sensitivity in depancreatized dogs. Diabetes 1999, 48, 1045-1053.
51. (d) Pospisilik, J. A.; Stafford, S. G.; Demuth, H.-U.; McIntosh, H. S.; Pederson, R. A. Long-Term Treatment with Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat - A Euglycemic-Hyperinsulinemic Clamp Study. Diabetes 2002, 51, 2677-2683.
52. (a) Burcelin, R.; Da Costa, A.; Drucker, D.; Thorens, B. Glucose competence of the hepatoprotal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001, 50, 1720-1728.
53. (b) Balkan, B.; Li, X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am. J. Physiol. Regul. Integ. Comput. Physiol. 2000, 279: R1449-R1454.
54. (a) Juana, F.; Valdeolmillos, M. Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic β-cells recorded in vivo. Diabetes 1999, 48 (4), 754-757.
55. (b) Nauck, M. A.; Heimessat, M. M.; Behle, K.; Holst, J. J.; Nauck, M. S.; Ritzel, R.; Hufner, M.; Schmiegel, Wolff, H. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 2002, 87 (3), 1239-1246.
56. These nonsubstrate DPP-IV inhibitors provide low micromolar IC50's, and, except for refs 20(a) and 20(b), contain a protonatable amine: (a) Shimazawa, R.; Takayama, H.; Kato, F.; Kato, M.; Hashimoto, Y. Nonpeptide small-molecular inhibitors of Dipeptidyl Peptidase IV; N-phenylphthalimide analogues. Bioorg. Med. Chem. Lett. 1999, 9, 559-562.
57. (b) Miyachi, H.; Kato, M.; Kato, F.; Hashimoto, Y. Novel potent nonpeptide aminopeptidase N inhibitors with a cyclic imide skeleton. J. Med. Chem. 1998, 41, 3, 263-265.
58. (c) Yamada, M.; Okagaki, C.; Higashijima, T.; Tanaka, S.; Ohnuki, T.; Sugita, T. A potent dipeptide inhibitor of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1998, 8, 1537-1540.
59. (d) Coppola, G. M.; Zhang, Y. L.; Schuster, H. F.; Russell, M. E.; Hughes T. E. 1-Aminomethylisoquinoline-4-carboxylates as novel Dipeptidyl Peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1555-1558.
60. (e) Kanstrup, A. B.; Christiansen, L. B.; Lundbeck, J. M.; Kristiansen; M. Preparation of piperazinylpurinediones as inhibitors of dipeptidylpeptidase IV. Patent WO 02002560, July 4th, 2002.
61. Irreversible oligopeptides with the N-terminal X-Pro-X sequence (low micromolar IC50) - Rahfeld, J.; Schierhorn, M.; Hartrodt, B.; Neubert, K.; Heins, J. Are Diprotin A and (Ile-Pro-Ile) and Diprotin B (Val-Pro-Leu) Inhibitors or Substrates of Dipeptidyl Peptidase IV? Biochim. Biophys. Acta 1991, 1076, 314-316.
62. Suicide substrate (latent quinoniminium methide electrophile - large cyclopeptide). Nguyen, C.; Blanco, J.; Mazaleyrat, J. P.; Krust, B.; Callebaut, C.; Jacotot, E.; Hovanessian, A. G.; Wakselman, M. Specific and Irreversible Cyclopeptide Inhibitors of Dipeptidyl Peptidase IV Activity of the T-Cell Activation Antigen CD26. J. Med. Chem. 1998, 41, 2100-2110.
63. Heins, J.; Welker, P.; Schönlein, C.; Born, I.; Hartrodt, B.; Neubert, K.; Tsuru, D.; Barth, A. Mechanism of Proline-Specific Proteinases; (I) Substrate Specificity of Dipeptidyl Peptidase IV from Pig Kidney and Protein-Specific Endopeptidase from Flavobacterium meningosepticum. Biochim. Biophys. Acta 1988, 954, 161-169.
64. (a) Barth, A.; Heins, J.; Fischer, G.; Neubert, K.; Schneeweiss, B. Dipeptidyl-peptidase IV: mechanism and specificity of the substrate cleavage. Mol. Cell. Regul. Enzyme Act., Part 1-3 1984, 46, 297-339.
65. (b) Schön, E.; Born, I.; Demuth, H.-U.; Faust, J.; Neubert, K.; Steinmetzer, T.; Barth, A.; Ansorge, S. Dipeptidyl Peptidase IV in the Immune System., Biol. Chem. Hoppe-Seyler 1991, 372, 305-311.
66. For comprehensive reviews on DPP-IV inhibitors, please see the following. (a) Villhauer, E. B.; Coppola, G. M.; Hughes, T. E. DPP-IV inhibition and Therapeutic Potential. Annu. Rep. Med. Chem. 2001, 36, 191-200.
67. (b) Augustyns, K.; Bal, G.; Thonus, G.; Belyaev, A.; Zhang, X. M.; Bollaert, W.; Lambeir, A. M.; Durinx, C.; Goossens, F.; Haemers A. The Unique Properties of Dipeptidyl-Peptidase IV (DPP-IV/CD26) and the Therapeutic Potential of DPP-IV Inhibitors Curr. Med. Chem. 1999, 6, 311-327.
68. (c) Snow, R. J.; Bachovchin, W. W. Boronic acid inhibitors of dipeptidyl peptidase IV; a new class of immunosuppressive agents. Adv. Med. Chem. 1995, 3, 149-177.
69. Jenkins, P. D.; Jones, D. M. DP-IV-serine protease inhibitors, Patent WO 95/15309, June 8th, 1995.
70. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D. 2-Cyanopyrrolidides as potent, stable inhibitors of Dipeptidyl Peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, (10), 1163-1166.
71. Li, J.; Wilk, E.; Wilk, S. Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of Dipeptidyl-Peptidase IV (CD26). Arch. Biochem. Biophys. 1995, 323 (1), 148-154.
72. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D. 4-Cyanothiazolidides as very potent, stable inhibitors of Dipeptidyl Peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, (22), 2745-2748.
73. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone M. D.; Russell M. E.; Weldon, S. C.; Hughes T. E. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]- acetyl-2-(S)-pyrrolidine-carbonitrile: a Potent, Selective and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, J. Med. Chem. 2002, 45, 2362- 2368.
74. Villhauer, E. B. N-(Substituted glycly)-2-cyanopyrrolidides, Pharmaceutical compositions containing them and their use in inhibiting Dipeptidyl Peptidase-IV. US 6,011,155, January 4th, 2000.
75. Villhauer, E. B. N-(Substituted glycly)-2-cyanopyrrolidides, Pharmaceutical compositions containing them and their use in inhibiting Dipeptidyl Peptidase-IV. US 6,166,063, December 26th, 2000.
76. Villhauer, E. B. N-(Substituted glycly)-2-cyanopyrrolidides, Pharmaceutical compositions containing them and their use in inhibiting Dipeptidyl Peptidase-IV. US 6,432,969, August 13th, 2002.
77. ORTEP drawings and atomic coordinate information of NVPDPP728 (8c) and NVP-LAF237 (12j) atomic coordinate information can be obtained from Supporting Information of ref 30 and this paper, respectively.
78. Described in Experimental Section.
79. Hughes, T. E.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Villhuaer, E. B. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of Dipeptidyl Peptidase IV. Biochemistry 1999, 38, 11597-11603.
80. Augustyns, K. J. L.; Lambeir, A. M.; Borloo, M.; De Meester, I.; Vedernikova, I.; Vanhoof, G.; Handriks, D.; Scharpé, S.; Haemaers, A. Pyrrolidides; synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur. J. Med. Chem. 1997, 32, 301-309.
81. PPCE and DPP-II are the standard enzymes in DPP-IV selectivity studies. (a) Belyaev, A.; Zhang, X.; Augustyns, K.; Lambeir, A. M.; De Meester, I.; Verdernikova, I.; Scharpé, S.; Haemers, A. Structure-Activity Relationship of Diaryl Phosphonate Esters a Potent Irreversible Dipeptidyl Peptidase IV Inhibitors. J. Med. Chem. 1999, 42, 1041-1052.
82. (b) Sedo, A.; Malik, R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities. Biochim. Biophys. Acta 2001, 1550, 107-116.
83. Rasmussen, H. P.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analogue. Nature Struct. Biol. 2003, 10 (1), 19-25.
84. (a) Rothenberg, P.; Kalbag, J.; Smith, H. T.; Gingerich, R.; Nedelman, J.; Villhauer, E.; McLeod, J.; Hughes, T. Treatment with a DPP-IV Inhibitor, NVP-DPP728, Increases Prandial Intact GLP-1 Levels and Reduces Glucose Exposure in Humans. Diabetes 2000, 49, (1), A39.
85. (b) Ahrén, B.; Sinonsson, E.; Larsson, H.; Landin-Oisson, M.; Torgeirsson, H.; Jansson, P. A.; Sandqvist, M.; Båvenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of Dipeptidyl Peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 2002, 25 (5), 869-875.
86. Reimer, M. K.; Holst, J. J.; Ahrén, B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 2002, 146, 717-727.
87. Reisher, S. R.; Hughes, T. E.; Ordovas, J. M.; Schaefer, E. J.; Feinstein, S. I. Increased expression of apolipoprotein genes accompanies differentiation in the intestinal cell line Caco-2. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5757-5761.
88. Kubota, T.; Flentke, G. R.; Bachovchin, W. W.; Stollar, B. D. Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin. Exp. Immunol. 1992, 89, 192-197.
89. Macnair, R. D.; Kenny, A. J. Proteins of the Kidney Microvillar Membrane: The amphipathic Form of Dipeptidyl Peptidase IV. Biochem. J. 1979, 179, 379-395.
90. Mantle, D. Characterization of dipeptidyl and tripeptidyl aminopeptidases in human kidney soluble fraction. Clin. Chim. Acta 1991, 196, 135-142.
91. DeMeester, I.; Vanhoof, G.; Lambeir, A. M.; Scharpe, S. Use of immobilized adenosine deaminase for the rapid purification of native human CD26/dipeptidyl peptidase IV. J. Immunol. Methods 1996, 189, 99-105.
92. Nagatsu, T.; Sakai, T.; Kojima, K.; Araki, E.; Sakakibara, S.; Fukasawa, K.; Harada, M. A sensitive and specific assay for dipeptidyl-aminopeptidase II in serum and tissues by liquid chromatography-fluorometry. Anal. Biochem. 1985, 147, 80-85.
93. Momand, J.; Clarke, S. Rapid degradation of D- and L-succinimide- containing peptides by a post-proline endopeptidase from human erythrocytes. Biochemistry 1987, 26, 7798-7805.
94. Deacon, C. F.; Hughes, T. E.; Holst, J. J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide I in the anesthetized pig. Diabetes 1998, 47, (5), 764-769.